Hormone Replacement Therapy: A 2026 Guide for Women & Men

Hormone replacement therapy is one of the most asked-about and most misunderstood treatments in medicine. For women approaching or in menopause, the questions usually involve hot flashes, sleep disruption, mood, vaginal dryness, and bone protection, layered on top of decades-old fears about breast cancer and cardiovascular risk. For men in their 40s, 50s, and 60s, the questions involve fatigue, low libido, body composition changes, and whether testosterone replacement is the answer or a marketing trap.

This is our cluster hub on hormone replacement therapy, written for adults trying to make a real decision rather than collect more confusing internet opinions. It covers the basics of how the major sex hormones work, what perimenopause and andropause actually look like, the modern evidence around HRT and TRT, the delivery methods (pellets, patches, creams, injections, oral), how we monitor patients, and what costs to expect. It links to our deeper guides on bioidentical hormone pellets cost, HRT for women in their 40s, and estrogen patch vs pill.

The full menu of HRT and TRT options at our Mission Viejo clinic lives on the hormone replacement therapy service page. This hub is the explanation of why and how, written by clinicians who treat hormone deficiency every day.

The short version: Hormone replacement therapy (HRT) restores hormones the body has stopped producing in adequate amounts, most commonly estrogen and progesterone for women in perimenopause or menopause, and testosterone for men with documented hypogonadism. Modern evidence supports HRT for symptom relief, bone protection, and quality of life when started in the right window (typically within 10 years of menopause onset or before age 60). The original Women’s Health Initiative scare from 2002 has been substantially reinterpreted; risk profile depends on type of hormone, route of delivery, age at initiation, and individual health factors. Pellets, patches, creams, injections, and gels are all real options with different trade-offs. Cost in 2026 ranges from $30 monthly for a generic estrogen patch to $300 to $500 every 3 to 6 months for a pellet protocol.

What this guide covers

1. Hormone basics: estrogen, progesterone, testosterone
2. Perimenopause and menopause
3. Andropause and male hypogonadism
4. Symptom screening and labs
5. Types of HRT: BHRT, conventional, compounded
6. Delivery methods: pellets, patches, creams, injections
7. Benefits and the modern evidence
8. Risks and the WHI in context
9. Who is a candidate
10. Monitoring on therapy
11. Cost in 2026
12. FAQ

Hormone basics

The three hormones most relevant to HRT and TRT are estrogen, progesterone, and testosterone. All three are produced by both men and women, in different ratios. Estrogen is the dominant female sex hormone; the most clinically important form is estradiol. Progesterone balances estrogen, supports sleep, and protects the uterus when estrogen is replaced. Testosterone is the dominant male sex hormone but plays meaningful roles in women too: libido, muscle mass, mood, and energy.

Hormone production declines with age. In women, the decline is steep and often abrupt; ovarian function diminishes through perimenopause and largely stops at menopause (defined as 12 consecutive months without a period). In men, the decline is gradual; testosterone falls roughly 1 to 2% per year after about age 30, with a subset developing clinical hypogonadism by their 40s, 50s, and beyond.

Hormone replacement is not about chasing youthful numbers regardless of age or context. It is about restoring physiologic levels in patients who have documented deficiency and bothersome symptoms, with monitoring to ensure the treatment is doing more good than harm.

Perimenopause and menopause

Perimenopause is the transition period leading up to menopause, lasting on average 4 to 8 years. It typically begins in a woman’s mid-40s but can start in the late 30s. Hormonal fluctuations during perimenopause are erratic; estrogen and progesterone can swing widely from cycle to cycle. The symptoms are often more disruptive than menopause itself: irregular periods, hot flashes that come and go, sleep disturbance, anxiety or depression, brain fog, joint pain, weight gain (especially abdominal), changes in libido, and changes in skin texture and hair.

Menopause is officially diagnosed at 12 months without a period; the average age in the United States is 51. Symptoms after menopause often persist or worsen: vasomotor symptoms (hot flashes, night sweats), genitourinary syndrome of menopause (vaginal dryness, urinary symptoms, painful intercourse), sleep disruption, mood changes, and accelerated bone loss. Many of these are highly responsive to appropriately dosed HRT.

The North American Menopause Society and the Endocrine Society have aligned over the past decade on a clear position: hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome, and it carries a favorable risk-benefit profile when initiated in healthy women under 60 or within 10 years of menopause onset (NAMS 2022 Position Statement).

Andropause and male hypogonadism

Male hypogonadism is the medical term for clinically low testosterone with consistent symptoms. The Endocrine Society defines it by repeated morning total testosterone levels below the lower limit of normal (typically below 264 ng/dL in most assays) plus symptoms: low libido, erectile dysfunction, decreased morning erections, fatigue, depressed mood, decreased muscle mass, increased body fat, and reduced exercise performance.

“Andropause” is a popular term for age-related testosterone decline; it is not a formal diagnosis on its own. Many men in their 40s and 50s have lower testosterone than they did at 25 but normal symptoms; many have symptoms but borderline labs that improve with sleep, weight management, and treatment of underlying conditions like sleep apnea. We do not start TRT on a single low test or on symptoms alone. We confirm with two morning labs, screen for reversible causes, and assess overall risk profile.

The TRAVERSE trial, published in 2023, was the largest cardiovascular safety trial of testosterone therapy in middle-aged and older men with hypogonadism. It found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events over an average of 22 months (Lincoff et al., NEJM 2023). That result reframed the risk discussion around TRT in eligible men.

Symptom screening and labs

Our hormone evaluation starts with a structured symptom inventory and a comprehensive labs panel. For women in or approaching perimenopause, baseline labs typically include estradiol, FSH, LH, progesterone (if cycling), TSH and free T4, vitamin D, fasting glucose and A1c, lipid panel, comprehensive metabolic panel, complete blood count, and sex hormone binding globulin. For symptomatic men, the panel includes total and free testosterone (drawn between 7 and 10 a.m.), LH, FSH, prolactin, estradiol, PSA (for men over 40), CBC, and a standard metabolic and lipid panel.

Lab values without symptoms are not enough to start hormone therapy. Symptoms without lab confirmation are not enough either. The diagnosis lives in the combination, plus a thoughtful conversation about what the patient is experiencing, what other contributors might be at play, and what realistic outcomes look like.

Types of HRT

Three terms get used loosely and often interchangeably; they are not the same.

Conventional HRT uses FDA-approved estrogen and progesterone (or progestin) products, available at any retail pharmacy. Examples include estradiol patches (Vivelle, Climara, Minivelle), oral estradiol, conjugated equine estrogens (Premarin), and progesterone (Prometrium, micronized progesterone). These products have decades of safety and efficacy data and are appropriate for the majority of women.

Bioidentical hormone replacement therapy (BHRT) refers to hormones that are molecularly identical to those produced by the human body. Many FDA-approved products (estradiol, micronized progesterone, testosterone) are bioidentical by this definition. The term is sometimes used more narrowly to mean compounded bioidentical hormones, prepared by compounding pharmacies in custom doses or combinations not commercially available.

Compounded HRT is custom-formulated by a compounding pharmacy. It has a role for patients who need a specific dose, combination, or delivery form not available commercially. The trade-off is that compounded hormones are not FDA-approved and quality control varies between pharmacies. We use licensed compounding pharmacies that test product identity and potency, and we reserve compounding for clinical situations where it adds real value.

Delivery methods

Patches

Estradiol patches deliver hormone transdermally, bypassing first-pass liver metabolism. This route is generally preferred for women with risk factors for blood clots or stroke because it avoids the increased clotting factors associated with oral estrogen. Patches are changed once or twice weekly. Doses range from 0.025 to 0.1 mg. See our estrogen patch vs pill guide for the practical comparison.

Oral

Oral estradiol and oral conjugated estrogens are convenient, well-tolerated, and inexpensive. They go through first-pass liver metabolism, which slightly increases clotting risk and triglyceride production compared with transdermal routes. Oral micronized progesterone, often taken at bedtime for its mild sedative effect, is the most common progesterone formulation we use.

Creams and gels

Topical estradiol gels (EstroGel, Divigel) and creams provide flexible dosing applied to the skin daily. They share the transdermal advantage with patches. Vaginal estrogen creams and tablets treat genitourinary syndrome locally with minimal systemic absorption and a very favorable safety profile. Compounded transdermal creams are also commonly used.

Pellets

Pellets are small subcutaneous implants of estradiol or testosterone (or both, in different pellets), placed in the upper buttock under local anesthesia. They release hormone steadily for 3 to 6 months, eliminating the need for daily or weekly application. Pellets are appealing for patients who want consistent levels without the routine. The downside is that doses cannot be adjusted between insertions, so getting the dose right requires careful initial dosing and monitoring. We cover this in detail in our bioidentical hormone pellets cost page.

Testosterone injections

Testosterone cypionate or enanthate injections are the most common TRT delivery method for men. Doses are typically 100 to 200 mg weekly or 80 to 100 mg twice weekly to smooth out levels. Subcutaneous injection is increasingly common over intramuscular for patient comfort. Self-administration after training is standard.

Testosterone gels and patches

Daily transdermal testosterone (AndroGel, Testim, Axiron, patches) is an alternative to injections. The trade-offs are daily application, the need to avoid skin-to-skin transfer to women and children, and somewhat less consistent levels than injections.

Benefits and the modern evidence

For women starting HRT in the appropriate window (under 60 or within 10 years of menopause onset), the documented benefits include relief from vasomotor symptoms, improvement in genitourinary symptoms, reduction in fracture risk, improved sleep and mood, and possibly improved cardiovascular outcomes. The Mayo Clinic’s overview of menopause hormone therapy outlines current consensus on benefits and risks (Mayo Clinic Hormone Therapy).

For men with documented hypogonadism, TRT improves libido, energy, mood, lean body mass, and bone density. Trials have shown improvements in fatigue and physical function in older men with low testosterone. The TRAVERSE trial reassured the field that cardiovascular risk in eligible men is not increased; prostate cancer risk in men without prior prostate disease appears not to be elevated based on current data.

Risks and the Women’s Health Initiative in context

The 2002 Women’s Health Initiative (WHI) press release reported increased risks of breast cancer, stroke, and cardiovascular events in women taking combined conjugated estrogen plus medroxyprogesterone, and the field reacted dramatically. HRT prescribing dropped by more than half. What we now understand: the WHI enrolled women with a mean age of 63, more than a decade past typical menopause, and used a specific oral conjugated estrogen plus a synthetic progestin. The results do not generalize to women starting transdermal estradiol with micronized progesterone within 10 years of menopause onset, who have a meaningfully different risk profile.

Modern risk factors that matter: age at initiation, type and route of estrogen, type of progesterone or progestin, dose, duration, and individual factors (smoking, BMI, family history, clotting risk, breast cancer risk). We talk through all of these during the consultation. We do not push HRT on patients with significant contraindications. We do not withhold it from patients who are appropriate candidates because of a 23-year-old headline that has been substantially revised.

For TRT, the meaningful risks include erythrocytosis (elevated hematocrit), worsening of untreated sleep apnea, fertility suppression (which matters for men still wanting children), acne, and possible aggravation of pre-existing prostate disease. We monitor regularly and adjust dose accordingly.

Who is a candidate?

For women: symptomatic perimenopause or menopause, no absolute contraindications (active or recent breast or endometrial cancer, undiagnosed vaginal bleeding, active liver disease, recent venous thromboembolism, uncontrolled hypertension), and an honest discussion of personal risk factors.

For men: documented hypogonadism on at least two morning labs plus consistent symptoms, no untreated severe sleep apnea, no active prostate or breast cancer, hematocrit within an acceptable range, and a plan for fertility if relevant.

Monitoring on therapy

For women on HRT, we typically check labs at 3 months, 6 months, then annually if stable. We track symptoms, blood pressure, and any breakthrough bleeding. Mammography continues per standard age-based guidelines.

For men on TRT, we check labs at 3 months, 6 months, then every 6 to 12 months: total testosterone (trough), hematocrit, PSA (if over 40), estradiol, and a metabolic panel. Dose adjustments are based on labs plus how the patient feels and what the original target symptoms looked like.

Cost in 2026

Cost varies dramatically by route and whether insurance covers the medication.

• Generic estradiol patch: $30 to $80 per month, often partially covered by insurance
• Oral estradiol or conjugated estrogens: $20 to $60 per month generic
• Compounded estradiol/progesterone cream: $40 to $100 per month
• Estradiol pellets (women): $300 to $500 per insertion every 3 to 4 months
• Testosterone pellets (men): $750 to $1,500 per insertion every 4 to 6 months
• Testosterone cypionate injection (men): $30 to $150 per month with insurance, $80 to $200 cash
• Initial consultation and labs: $200 to $500 depending on which panels are run

Most patients spend less than they expect on HRT once on a stable protocol. Most men spend less on TRT than they spent on symptom workups before treatment. The first visit is the most expensive because of the comprehensive lab panel.

Insurance coverage varies. Most commercial plans cover generic estradiol patches, oral estradiol, and testosterone cypionate when there is documented hypogonadism with appropriate ICD-10 coding. Plans rarely cover compounded hormones or pellet insertions; both are usually paid out of pocket. We help patients run benefits checks at the consult and choose a protocol that fits both clinical needs and financial reality.

Pellet pricing in particular varies widely between practices. Some markup pellets aggressively; others price them close to cost. Always ask what you are paying for: the pellet itself, the insertion procedure, and the follow-up labs. Bundled pricing is fine if the components are disclosed.

FAQ

Talk to a clinician at OC Weight Loss & Med Spa

If you are weighing HRT or TRT and want a careful, evidence-based conversation rather than a sales pitch, the best next step is a consult with comprehensive labs and a real symptom inventory. Our team in Mission Viejo offers conventional and bioidentical HRT, pellets, patches, creams, and injectable testosterone through our hormone replacement therapy service. We treat men and women across Orange County, including Irvine, Laguna Niguel, Lake Forest, and Newport Beach.

Book a free consultation

Medically reviewed by the clinical team at OC Weight Loss & Med Spa. Last updated: June 12, 2026.